Serum vitamin D receptor and High Mobility Group Box-1 (HMGB1) levels in HIV-infected patients with different immunodeficiency status: A cross-sectional study.
HIV infection
HMGB1 protein
Immunodeficiency
Vitamin D receptor
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
12
2020
revised:
03
02
2021
accepted:
04
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
HIV-AIDS patients typically have hypovitaminosis D. Vitamin D is a key mediator in inflammatory and infectious diseases, which VDR mediates its biological effect. High-mobility group box 1 protein (HMGB1) modulates HIV-1 replication in vitro. Vitamin D played a role in inhibiting HMGB1 secretion in the animal study. This study aimed to examine differences and correlation of vitamin D receptor and HMGB1 protein levels in HIV patients with mild and severe immunodeficiency and healthy control participants. This study using a cross-sectional design conducted at Volunteer Counseling and Testing (VCT) Clinic in Mataram, West Nusa Tenggara, Indonesia, from January to June 2020. Three groups of study participants were classified as HIV patients with severe immune deficiency (SID), HIV patients with mild immune deficiency (MID), and healthy controls (HC). Mean level of vitamin D receptor in SID HIV group was 25.89 ± 3.95 ng/ml, lower than those in MID-HIV group; 33.72 ± 1.69 ng/ml and in HC group; 50.65 ± 3.64 ng/ml. Mean levels of HMGB1 protein in the SID HIV group were 3119.81 ± 292.38 pg/ml higher than those in the MID HIV group 1553.55 ± 231.08 pg/ml and HC 680.82 ± 365.51 pg/ml. There was a significant and strong negative correlation (r = -0.932) between vitamin D receptor and HMGB1 levels ( Strong negative correlation between VDR and HMGB1 in different immunodeficiency statuses suggesting an important role of vitamin D in inflammation control in HIV infection. However, it needs to be confirmed in a further prospective study.
Sections du résumé
BACKGROUND
BACKGROUND
HIV-AIDS patients typically have hypovitaminosis D. Vitamin D is a key mediator in inflammatory and infectious diseases, which VDR mediates its biological effect. High-mobility group box 1 protein (HMGB1) modulates HIV-1 replication in vitro. Vitamin D played a role in inhibiting HMGB1 secretion in the animal study.
OBJECTIVES
OBJECTIVE
This study aimed to examine differences and correlation of vitamin D receptor and HMGB1 protein levels in HIV patients with mild and severe immunodeficiency and healthy control participants.
METHODS
METHODS
This study using a cross-sectional design conducted at Volunteer Counseling and Testing (VCT) Clinic in Mataram, West Nusa Tenggara, Indonesia, from January to June 2020. Three groups of study participants were classified as HIV patients with severe immune deficiency (SID), HIV patients with mild immune deficiency (MID), and healthy controls (HC).
RESULTS
RESULTS
Mean level of vitamin D receptor in SID HIV group was 25.89 ± 3.95 ng/ml, lower than those in MID-HIV group; 33.72 ± 1.69 ng/ml and in HC group; 50.65 ± 3.64 ng/ml. Mean levels of HMGB1 protein in the SID HIV group were 3119.81 ± 292.38 pg/ml higher than those in the MID HIV group 1553.55 ± 231.08 pg/ml and HC 680.82 ± 365.51 pg/ml. There was a significant and strong negative correlation (r = -0.932) between vitamin D receptor and HMGB1 levels (
CONCLUSIONS
CONCLUSIONS
Strong negative correlation between VDR and HMGB1 in different immunodeficiency statuses suggesting an important role of vitamin D in inflammation control in HIV infection. However, it needs to be confirmed in a further prospective study.
Identifiants
pubmed: 33664952
doi: 10.1016/j.amsu.2021.02.020
pii: S2049-0801(21)00123-0
pmc: PMC7900012
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102174Informations de copyright
© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interests.
Références
Innate Immun. 2013 Jun;19(3):290-7
pubmed: 23070967
Int J Microbiol. 2012;2012:263836
pubmed: 22719767
PLoS One. 2014 May 02;9(5):e96695
pubmed: 24792400
Mol Med Rep. 2018 Feb;17(2):2915-2920
pubmed: 29257249
Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):432-8
pubmed: 26414080
Photochem Photobiol Sci. 2017 Mar 16;16(3):314-338
pubmed: 28078341
Curr HIV Res. 2011 Jan;9(1):6-10
pubmed: 21198433
J Gen Virol. 2010 Jul;91(Pt 7):1800-9
pubmed: 20200191
AIDS. 2007 Apr 23;21(7):869-71
pubmed: 17415043
Clin Ther. 2017 May;39(5):930-945
pubmed: 28457494
AIDS. 2013 Feb 20;27(4):573-8
pubmed: 23095316
Antivir Ther. 2011;16(4):555-63
pubmed: 21685543
Front Immunol. 2019 Sep 25;10:2291
pubmed: 31611877
Front Immunol. 2018 Mar 12;9:458
pubmed: 29593721
Blood. 2003 Apr 1;101(7):2652-60
pubmed: 12456506
AIDS. 2010 Jul 17;24(11):1733-7
pubmed: 20502315
Front Immunol. 2017 Oct 16;8:1308
pubmed: 29085368
Int J Clin Exp Pathol. 2016 Aug;9(8):8506-8512
pubmed: 32699567
J Infect Dis. 2014 Jul 15;210(2):244-53
pubmed: 24799602
Curr HIV/AIDS Rep. 2011 Sep;8(3):133-41
pubmed: 21647555
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
Drug Des Devel Ther. 2016 Dec 28;11:91-102
pubmed: 28096657
AIDS. 2011 Jun 19;25(10):1305-15
pubmed: 21522006
Can J Physiol Pharmacol. 2015 May;93(5):363-8
pubmed: 25741906